Navigation Links
TEI Biosciences' PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
Date:2/18/2010

BOSTON, Feb. 18 /PRNewswire/ -- TEI Biosciences Inc. announced today that its PriMatrix™ Dermal Repair Scaffold has been awarded the coveted American Podiatric Medical Association's (APMA) Seal of Approval.  PriMatrix is a bioactive collagen matrix used in the management of diabetic and venous ulcers, second-degree burns, and surgical and trauma wounds.

APMA is the nation's leading professional society for foot and ankle specialists. The Seal of Approval Program was created to inform podiatric physicians and consumers about products whose quality, safety, and effectiveness promote good foot health.  In order to qualify for the Seal of Approval, PriMatrix had to pass a thorough scientific evaluation by a panel of APMA members. The results were then evaluated by a committee of Doctors of Podiatric Medicine who decided to grant TEI the use of the Seal for PriMatrix.

"TEI is very excited about APMA's Seal of Approval award for PriMatrix," said Yiannis Monovoukas, Ph.D., TEI's Chairman, President and CEO.  "PriMatrix is a novel biologic product proven safe and effective in treating many types of skin wounds in several thousand patients," said Dr. Monovoukas.  "The addition of the APMA's Seal of Approval to PriMatrix is an affirmation of our commitment to developing innovative healthcare products that better meet the needs of physicians and their patients."  

About PriMatrix™ Dermal Repair Scaffold

PriMatrixDermal Repair Scaffold is an acellular collagen matrix derived from fetal bovine dermis, one of the purest forms of collagen available. Due to its bioactive collagen matrix technology, PriMatrix is an ideal material for the management of numerous types of wounds as it supports cell repopulation and revascularization processes essential to wound healing. PriMatrix is rich in Type III collagen, a natural component of fetal dermis that aids in tissue healing and regeneration.

PriMatrix is intended for the management of wounds that include: partial and full thickness wounds; pressure, diabetic, and venous ulcers; second-degree burns; surgical wounds; trauma wounds; tunneled/undermined wounds; and draining wounds.  

For more information, please visit TEI's website at www.teibio.com.

About TEI Biosciences Inc.

A Boston-based, privately-held, leading biomedical company, TEI Biosciences Inc. has applied its expertise in regenerative medicine to develop and commercialize novel biologic products for a broad spectrum of soft tissue repair, regeneration, and reinforcement applications -- from plastic and reconstructive surgery to dura, tendon, and hernia repair, and wound management.

TEI sells its products directly and through partnerships with some of the world's major medical device companies.  TEI's marketed products include:

  • SurgiMend® for plastic and reconstructive surgery, breast reconstruction, muscle flap reinforcement, hernia repair, and abdominal wall reconstruction;
  • PriMatrix™ for skin wound management;
  • Durepair® for cranial and spinal dura mater repair (marketed by Medtronic);
  • Xenform™  for pelvic floor reconstruction (marketed by Boston Scientific);
  • TissueMend® for tendon augmentation (marketed by Stryker).

SOURCE TEI Biosciences Inc.

RELATED LINKS
http://www.teibio.com

'/>"/>

SOURCE TEI Biosciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
2. YM BioSciences granted two US patents for AeroLEF(R)
3. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
4. YM BioSciences reports second quarter 2010 operational and financial results
5. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
6. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
7. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
8. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
9. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
10. YM BioSciences announces result of Cytopia shareholder vote
11. Profectus Biosciences to Present at Key Investor Conference in January 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Bactana Animal Health, ... in the world’s food supply through enhancement of the gut microbiota, today announced the ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number ...
(Date:3/29/2017)... 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the ... new risk stratification test for breast cancer, via its ... ("IDL"). BreastSentry incorporates a blood-based biomarker test with a sophisticated ... developing breast cancer.   ... BreastSentry measures the fasting plasma levels of ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... , March 2, 2017 Who risk ... lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
Breaking Biology News(10 mins):